In fact, several studies in animal models for obesity and NAFLD have recently demonstrated the beneficial effects of pharmacological stimulation of FXR and TGR5 on hepatic steatosis and insulin resistance. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.